SOURCE: CTD Holdings, Inc.

CTD Holdings, Inc. Logo

January 08, 2015 07:00 ET

N. Scott Fine Named Board Chairman of Global Virus Network

CTD's Chairman of the Board Will Help GVN Continue to Build on Its Mission to Combat Worldwide Viral Threats

ALACHUA, FL--(Marketwired - January 08, 2015) - CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that distribute and manufacture cyclodextrin-based products, including the orphan drug designated Trappsol® Cyclo, today announced that board chairman N. Scott Fine has been elected Chairman of the Board of Directors of Global Virus Network (GVN), a non-profit organization whose mission is to combat current viral threats and emerging pandemic threats worldwide.

"Mr. Fine brings not only exceptional business skills and acumen to GVN but he has an undeniable passion for improving the health of the world's people. We are delighted to be able to call him colleague, partner and Chairman," said Robert C. Gallo, MD, GVN Co-Founder and Director of GVN's Center of Excellence at the Institute of Human Virology, University of Maryland School of Medicine. GVN President Sharon H. Hrynkow, PhD, is a member of CTD's Scientific Advisory Board.

Mr. Fine succeeds the outgoing GVN Board Chairman, attorney Timothy C. Moynahan, who will take on a new role as Board Vice Chairman.

"I am honored to have been elected by the Board of GVN as its Chairman, and I look forward to working with Dr. Gallo, Dr. Hrynkow, and the full Board, to continue to build GVN on the platform so well established through Tim Moynahan's leadership," said Mr. Fine.

Mr. Fine has been involved in Investment Banking for over 35 years, working on a multitude of debt and equity financings, buy and sell side M&A, strategic advisory work and corporate restructurings. He has worked with a number of companies in the healthcare, biotechnology and medical device sectors. Mr. Fine advised Research Medical, a specialty medical device manufacturer, on a strategic equity alliance with The Tempo Group of Jakarta, Indonesia. Research Medical was subsequently acquired by Baxter. Mr. Fine also was the lead investment banker on the Initial Public Offering for Med-Design Corporation, a specialty medical device company, which was later acquired by Specialized Health Products International, Inc.

Mr. Fine was appointed Chairman of the Board of Directors of CTD in 2014. The company's Trappsol Cyclo product is currently used to treat Niemann-Pick Type C, a rare and fatal disease in children.

"Scott's finance and healthcare experience has greatly helped CTD's biotechnology business grow and flourish," said Dr. Jeffrey Tate, President and CEO of CTD. "I have no doubt his expertise will be instrumental in helping GVN build on its vital work in combating viral diseases."

About the Company: 
CTD Holdings, Inc. is a family of biotechnology growth companies based on cyclodextrin chemistry. Its individual divisions distribute and manufacture the trademarked Trappsol® and Aquaplex® cyclodextrins, cyclodextrin derivatives, and cyclodextrin complexes for biotechnology and life science companies involved in research, pharmaceutical, medical device, cosmetics and nutrition markets. Sphingo Biotechnology, Inc. is developing Trappsol® Cyclo, an orphan drug designated product, for the treatment of Niemann-Pick Type C, a rare and fatal genetic disease in young children. NanoSonic Products, Inc. operates the world's only cGMP pulse drying facility for the production of ultra-pure cyclodextrin derivatives and pharmaceutical grade Aquaplex® cyclodextrin complexes. CTD, Inc. supplies cyclodextrins to biotechnology and life science researchers around the globe from the world's largest catalog of cyclodextrins. The companies offer a wide variety of cyclodextrin related manufacturing services to worldwide customers, including custom formulation, manufacturing, and commercial scale supply of pharmaceutical grade cyclodextrin complexes. For additional information, visit the Company's websites: and

About the Global Virus Network (GVN):
The Global Virus Network (GVN) is a non-profit, 501(c)(3) organization, comprised of leading medical virologists from 25 countries, and growing. The GVN's mission is to combat current viral threats and emerging pandemic threats through international collaborative research, training the next generation of medical virologists, and advocacy. For more information, please visit Follow us on Twitter @GlobalVirusNews

Safe Harbor Statement:
This press release contains "forward-looking statements" about the Company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the Company's future performance include the Company's ability to obtain additional capital to expand operations as planned, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing food and pharmaceutical grade products. These and other risk factors are described from time to time in the Company's filings with the Securities and Exchange Commission, including, but not limited to, the Company's reports on Forms 10-K and 10-Q. Unless required by law, the Company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

Contact Information